Chronic Pancreatitis: A progressive inflammatory disease of the pancreas characterized by persistent pain, exocrine and endocrine dysfunction, and an increased risk of pancreatic cancer. CBT-101 targets the inflammatory cascades driving pancreatic inflammation and fibrosis, aiming to halt disease progression and alleviate symptoms. Preclinical studies have shown promising reductions in inflammatory markers and tissue damage in multiple pancreatitis models.

Ulcerative Colitis: A major form of inflammatory bowel disease (IBD), causing chronic inflammation and ulceration of the colon, leading to severe symptoms such as abdominal pain and bloody diarrhea. CBT-101 modulates dysregulated immune responses in the gut, offering a potential oral therapy with improved efficacy and safety. Preclinical data indicate significant reductions in inflammatory cytokines and mucosal damage in colitis models.